Physician-scientist and Fellow of the AACR Academy William N. Hait, MD, PhD, encourages collaborations to intercept, prevent, and treat cancer. Throughout a varied career in academia and industry, Dr. Hait has kept his sights on benefiting patients.
Dr. Olufunmilayo Olopade, a physician-scientist and director of the Center for Clinical Cancer Genetics at the University of Chicago Medical Center seeks widespread use of testing to encourage prevention and early detection of deadly cancers.
An internationally recognized leader in clinical and translational research on breast cancer, Dr. Garber developed one of the first cancer risk and prevention clinics where programs are now being expanded to several types of cancer.
As a physician scientist and leader in the development of targeted therapies for cancer, Dr. Sawyers investigates the signaling pathways that drive the growth and drug resistance of cancer cells.
W. Kimryn Rathmell, MD, PhD, director of the Division of Hematology and Oncology at Vanderbilt University Medical Center in Nashville, has twice been awarded grants by the American Association for Cancer Research (AACR). “The AACR does a great job of identifying high-risk, high-reward research,” Dr. Rathmell said.
A renowned authority on hormones and their role in disease, Dr. Evans has conducted research that has led to the discovery of nearly 50 nuclear hormone receptors.
For Michael A. Caligiuri, MD, the 2017-2018 AACR President, it is unacceptable that advances in cancer care and treatment don’t benefit everyone equally. Dr. Caligiuri made cancer health disparities one of the signature issues of his tenure as AACR President.
Dr. Horwitz's contributions to the field encompass agents that have served as prototypes for some of the most important drugs currently in clinical use. Her most seminal contribution has been in the development of Taxol®, a drug isolated from the yew plant, Taxus brevifolia.
Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
James P. Allison, PhD: Untangling the complexities of the immune system to pioneer cancer immunotherapy.